首页 › 基金 › Madison Avenue Partners, LP › TBPH
Madison Avenue Partners, LP 对 TBPH 的持仓历史
THERAVANCE BIOPHARMA INC
Madison Avenue Partners, LP 在 Q2 2026 的 13F 申报中披露持有 TBPH(THERAVANCE BIOPHARMA INC)9,212,252 股,市值约 US$156.6M,约占其申报组合的 6.74%,在其申报持仓中市值排名第 6 位。 Madison Avenue Partners, LP 最近 12 个申报季度中有 12 个季度披露了 TBPH 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Madison Avenue Partners, LP 对 TBPH 的持仓演变
Madison Avenue Partners, LP 于 Q3 2023 首次披露 TBPH 持仓:7,012,226 股(约 US$60.5M)。 该持仓在 Q4 2025 达到峰值 9,511,150 股,市值约 US$178.0M。 在 12 次申报中,Madison Avenue Partners, LP 2 次增持、1 次减持、8 次保持不变。 最近一期申报(Q2 2026)显示持股 9,212,252 股、市值约 US$156.6M,环比减持 -298,898 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 7.01M | $60.52M | 新进 |
| Q4 2023 | 7.01M | $78.82M | 持有 |
| Q1 2024 | 7.01M | $62.90M | 持有 |
| Q2 2024 | 8.51M | $72.18M | 增持 |
| Q3 2024 | 9.51M | $76.66M | 增持 |
| Q4 2024 | 9.51M | $89.50M | 持有 |
| Q1 2025 | 9.51M | $84.93M | 持有 |
| Q2 2025 | 9.51M | $104.91M | 持有 |
| Q3 2025 | 9.51M | $138.86M | 持有 |
| Q4 2025 | 9.51M | $177.95M | 持有 |
| Q1 2026 | 9.51M | $154.37M | 持有 |
| Q2 2026 | 9.21M | $156.61M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 TBPH 与 13F 数据
TBPH(THERAVANCE BIOPHARMA INC)的行业分类暂缺。我们追踪的基金中还有 31 只申报持有 TBPH,申报仓位最大的包括:Weiss Asset Management LP (US$126.8M), Newtyn Management, LLC (US$58.4M), Irenic Capital Management LP (US$46.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 TBPH 的基金
- Weiss Asset Management LP 7.46M 股 · $126.77M · Q2 2026
- Newtyn Management, LLC 3.43M 股 · $58.38M · Q2 2026
- Irenic Capital Management LP 2.76M 股 · $46.94M · Q2 2026
- Oasis Management Co Ltd. 583.49K 股 · $9.92M · Q2 2026
更多关于 Madison Avenue Partners, LP
常见问题
How long has Madison Avenue Partners, LP held TBPH?
Madison Avenue Partners, LP has disclosed TBPH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Madison Avenue Partners, LP's current position in TBPH?
As of Q2 2026, Madison Avenue Partners, LP holds 9.21M shares of TBPH (THERAVANCE BIOPHARMA INC), valued at $156.61M, representing 6.74% of its reported portfolio and ranking #6.
Has Madison Avenue Partners, LP been buying or selling TBPH?
In the latest 13F filing (Q2 2026), Madison Avenue Partners, LP reduced its position in TBPH. The position peaked in Q4 2025 at 9.51M shares.
Which other funds hold TBPH?
Other major institutional holders of TBPH include Weiss Asset Management LP, Newtyn Management, LLC, Irenic Capital Management LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.